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Stretched healthcare budgets have been tensing up
patient access negotiations between healthcare payers
and manufacturers. Data and the associated evidence
available at registration are often deemed insufficient to
accurately estimate the real-life clinical outcomes and
budget impact. Payers want to reduce budget uncer-
tainty and manufacturers need to evolve in a competing
healthcare environment.
Risk-sharing agreements (RSAs) are on the rising
trend. Conceptually, RSAs have the remarkable advan-
tage of reducing payer exposure to the financial risks
associated with the introduction of a new healthcare
intervention. However, engaging in a RSA should be
cautiously thought through and planned as those con-
tracts entail important financial implications, notably for
the manufacturer. Monitoring costs are elevated and
might jeopardize the implementation [1].
Nowadays, most of the current RSAs tend to shift the
uncertainty around an expected outcome from the health-
care payer to the manufacturers. Although one cannot
refer to risk-sharing per se, manufacturers use it during
negotiations as an alternative to price reduction [2].
We will define the insurance approach in the stag-
gered financial evaluation of a potential RSA. The risk
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Figure 1 The risk embedded in healthcare contract did not simply shift from the payer to the manufacturer. An insurer stands behind the
manufacturer. It reimburses the payer if the risk realizes
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will be quantified from the point of view of three profes-
sional risk-takers (i.e. an investment bank, a reinsurer
and a pension fund) willing to insure the transaction
(Figure 1). Various formulas to split this risk-equivalent
cost (i.e. insurance premium) between a manufacturer
and a payer will be proposed (Figure 2). Budget gains
for switching from the actual situation to the three risk-
equivalent costs methodologies will be illustrated using
a fictive oncology product.
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Figure 2 When packaged with an insurance contract, treatment B is preferred to treatment A.
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